A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference6 articles.
1. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol;Grundy;J Am Coll Cardiol,2019
2. A highly durable RNAi therapeutic inhibitor of PCSK9;Fitzgerald;N Engl J Med,2017
3. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol;Ray;N Engl J Med,2017
4. Inclisiran for the treatment of heterozygous familial hypercholesterolemia;Raal;N Engl J Med,2020
5. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol;Ray;N Engl J Med,2020
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes;Cardiovascular Drugs and Therapy;2024-06-22
2. Molecular Therapies in Cardiovascular Diseases: Small Interfering RNA in Atherosclerosis, Heart Failure, and Hypertension;International Journal of Molecular Sciences;2023-12-26
3. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients;Expert Opinion on Drug Safety;2023-12-08
4. PCSK9 in extrahepatic tissues: What can we expect from its inhibition?;European Atherosclerosis Journal;2023-08-31
5. Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews;Medicine;2023-01-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3